Introduction
============

Radiotherapy (RT) has played an important role in the management of breast cancer by eradicating microscopic tumor cells not only for all of the patients treated with breast-conserving surgery but for selected patients treated with mastectomy \[[@b1-crt-2016-405]-[@b3-crt-2016-405]\]. Current guidelines generally recommend postmastectomy RT (PMRT) for locally advanced cancer (T3-T4) or four or more positive axillary lymph nodes (LNs) (N2 or higher) \[[@b1-crt-2016-405],[@b2-crt-2016-405],[@b4-crt-2016-405]\]. However, postoperative PMRT for early breast cancer (T1-T2) and limited nodal metastasis (N1) are controversial.

Studies have reported the effects of PMRT on tumor recurrence and mortality in patients with 1-3 axillary LNs, including the Danish Breast Cancer Cooperative Group trial and a recent meta-analysis by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) \[[@b5-crt-2016-405],[@b6-crt-2016-405]\]. The Danish trial showed the substantial benefit of PMRT on loco-regional recurrence (LRR) and overall survival in patients with N1 and N2 disease. EBCTCG analysis also showed a similar result such that PMRT to the chest wall and regional lymphatics reduced both recurrence and breast cancer mortality in patients with N1 and N2 disease, even when axillary dissection at least at level II was performed, and systemic therapy was given. Nonetheless, the use of PMRT has been controversial for all T1-T2/N1 patients. One reason is that the absolute risk of any type of recurrence has decreased with modern systemic therapy in recent decades. Another reason is related to breast cancer being not a single entity but biologically distinct diseases \[[@b7-crt-2016-405]-[@b9-crt-2016-405]\]. The biological subtype can also predict the risk of recurrence and response of treatment as well, although the current guidelines suggest the indication of PMRT based on only tumor and nodal stage. Large randomized trials or meta-analyses including the Danish trial and EBCTCG analysis did not address this issue.

The EBCTCG meta-analysis in 2005 showed that the avoidance of LRR led to a reduction of breast cancer mortality in node-positive patients treated with mastectomy and PMRT \[[@b10-crt-2016-405]\]. On the other hand, the updated analysis in 2014 showed that the avoidance of any first recurrence (AFR) led to a decrease in breast cancer mortality \[[@b5-crt-2016-405]\]. In this study, we investigated the risk factors for LRR as well as AFR in N1 patients after optimal systemic therapy but not PMRT, thus defining a subgroup of patients who may or may not benefit from PMRT.

Materials and Methods
=====================

This study was approved by the Korean Radiation Oncology Group (KROG 14-23) and Institutional Review Board of each participating institution. After the approval, we retrospectively reviewed the medical records of breast cancer patients treated with mastectomy without PMRT between 2005 and 2010 at 11 institutions in Korea. Patients with a tumor size ≤ 5 cm (pT1 and pT2) and 1-3 axillary LN metastases (pN1) were exclusively included in this study. We excluded patients who received neoadjuvant systemic treatment, had distant metastasis at diagnosis, had a history of malignancies other than thyroid cancer, or were diagnosed with bilateral breast cancer. A total of 1,382 breast cancer patients met the eligibility criteria.

Clinico-pathological information of eligible patients was collected; it included the age at diagnosis, menopausal status, tumor histology, tumor size, tumor grade, number of involved and examined LNs, and estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 status. The positivity of ER, PR, HER2, and Ki-67 was determined by immunohistochemical staining. HER2-positivity was defined as a 3+ immunohistochemical result or a 2+ immunohistochemical result confirmed by fluorescence *in situ* hybridization. The breast cancer subtypes were approximated based on hormone receptor status, HER2 status, and histologic grade. Because Ki-67 status data were incomplete (available only in 757 patients \[54.8%\]), we used the histologic grade as a surrogate for Ki-67 based on St. Gallen Expert Consensus \[[@b11-crt-2016-405]\]. The five surrogate biological subtypes were defined accordingly: luminal A (ER+ or PR+/HER2--/low-intermediate grade), luminal B (ER+ or PR+/HER2--/high grade), HER2+ (ER--/PR--/HER2+), luminal HER2 (ER+ or PR+/HER2+), and triple negative (TN) (ER--/PR--/HER2--).

The primary outcome of interest was AFR, irrespective of LRR or distant metastasis (DM). We defined local recurrence (LR) as tumor recurrence in the ipsilateral chest wall, and regional recurrence (RR) as recurrence in ipsilateral draining LNs (axillary, supraclavicular, or internal mammary LNs). LRR was defined as LR or RR or both. Following the EBCTCG meta-analysis, we used LRR as a first event for statistical analysis. Hereafter, LRR refers to LRR with or without synchronous DM. DM was defined as tumor recurrence outside regions identified as LRR sites. The information on date of death was taken from Korea's national database, in which death by breast cancer was not distinguished from death by other causes. Time to any recurrence or death was measured from the date of mastectomy.

Cumulative incidence function curves for AFR, LRR, and overall mortality were constructed using the Kaplan-Meier method, and comparisons between groups were performed using log-rank tests. Statistical analysis was performed using SPSS ver. 18.0 (SPSS Inc., Chicago, IL). p-values lower than 0.05 were deemed to indicate statistical significance.

Results
=======

1. Patient and tumor characteristics
------------------------------------

[Table 1](#t1-crt-2016-405){ref-type="table"} summarizes the demographic and clinico-pathologic parameters, as well as treatment details, of the study cohort. The median age at diagnosis was 48 years (range, 24 to 85 years). All 1,382 patients underwent mastectomy with clear resection margins, and 189 of these patients (13.7%) had resection margins less than 2 mm. The most common histology was invasive ductal carcinoma (97.5%). There were 820 T2 tumors (59.3%), and 547 high-grade tumors (39.6%). Complete axillary LN dissection was performed in 1,276 patients (92.3%), and sentinel LN biopsy alone was performed in 103 patients (7.5%). The median number of examined LNs was 15 (range, 1 to 64), and more than 10 LNs were examined in 1,107 patients (80.7%). In all, 813 patients (58.8%) had one involved LN, 371 (26.8%) had two involved LNs, and 198 (14.3%) had three involved LNs. There were 1,022 patients (74.0%) with positive hormone receptor status, and 14 of them did not receive hormone treatment. On the other hand, 38 of 360 patients with negative hormone receptor status did receive hormone treatment. There were 407 patients (29.5%) with positive HER2 expression; 62.1% of them (n=253) were treated with trastuzumab. In addition, 1,333 (96.5%) and 1,046 (75.7%) patients received adjuvant chemotherapy (83% received a taxane-containing regimen) and hormonal therapy, respectively. Eight patients (0.6%) did not receive systemic treatment. Adjuvant systemic treatment was delivered at the physician's discretion.

2. Tumor recurrence and death
-----------------------------

The median follow-up period was 5.9 years (range, 0.6 to 10.4 years). In total, 94 patients (6.8%) died, and 79 of them had experienced tumor recurrence before death. [Table 2](#t2-crt-2016-405){ref-type="table"} shows the sites of total recurrence. There were more distant recurrences (n=138) than LRRs (n=91). Of 91 LRRs, 17 were synchronous LR and RR. Fifty-seven patients experienced LRR as well as DM. Finally, 81 had isolated DM.

There were 173 AFRs, among which 53 (30.6%) were LRRs without DM, 38 (22.0%) were LRRs with DM, and 82 (47.4%) were DMs without LRR. The cumulative incidence curves of LRR, AFR, and overall mortality are illustrated in [Fig. 1](#f1-crt-2016-405){ref-type="fig"}. The cumulative incidence of AFR and LRR increased steeply within 5 years from the date of mastectomy, and the mortality curve was not particularly steep during the specific time period. The cumulative LRR rates at 5, 7, and 10 years were 6.1%, 7.7%, and 10.5%, respectively. Those for AFR at 5, 7, and 10 years were 12.0%, 13.8%, and 17.9%, respectively; and those for overall mortality at 5, 7, and 10 years were 4.5%, 6.9%, and 11.6%, respectively.

3. Effect of biological subtype on LRR and AFR
----------------------------------------------

When classified into five biological subtypes, luminal A was the most common subtype (40.1%), and the remaining four subtypes had similar proportions ([Table 1](#t1-crt-2016-405){ref-type="table"}). The 5-year AFR rates of luminal A, luminal B, HER2, luminal HER2, and TN were 8.2%, 11.7%, 10.5%, 11.2%, and 18.8%, respectively. And the 10-year AFR rates were 16.7%, 24.7%, 13.6%, 12.6%, and 25.5%, respectively ([S1 Fig. 1A](#SD1-crt-2016-405){ref-type="supplementary-material"}). The 5-year locoregional recurrence-free survival rates of luminal A, luminal B, HER2, luminal HER2, and TN were 4.3%, 9.5%, 5.9%, 5.3%, and 10.4%, respectively. And the 10-year AFR rates were 9.4%, 12.7%, 9.2%, 6.8%, and 14.6%, respectively ([S1 Fig. 1B](#SD1-crt-2016-405){ref-type="supplementary-material"}). In univariate analyses, the TN and luminal B subtypes predicted more LRR and AFR than the luminal A subtype (all, p \< 0.001) ([Table 3](#t3-crt-2016-405){ref-type="table"}).

Because the use of trastuzumab for HER2 patients was not covered with Korean national health insurance in the early period of enrollment, 253 of 407 HER2 patients (62.2%) were treated with trastuzumab. For this reason, we subdivided HER2-positive patients (among the HER2 and luminal HER2 subtypes) into those treated with and without trastuzumab. Thus, we reclassified those patients into five biological subtypes: luminal A, luminal B, HER2-- trastuzumab+, HER2--trastuzumab--, and TN. The results were similar to those of the former analysis in which the TN and luminal B subtypes had significantly more LRR and AFR than the luminal A subtype (all, p \< 0.001). There was slightly more LRR and AFR in the HER2 group without trastuzumab treatment than in the HER2 group with the treatment, but this difference was not statistically significant (p=0.674 and p=0.415, respectively).

4. Risk factors
---------------

The results of univariate and multivariate analyses of LRR and AFR are presented in [Table 3](#t3-crt-2016-405){ref-type="table"}. To facilitate the comparison between groups in multivariate analyses using the Cox proportional hazards model, the biological subtypes were redefined as binary variables: TN tumors and others (p=0.001) ([Table 3](#t3-crt-2016-405){ref-type="table"}).

Univariate analyses of LRR revealed that age ≤ 35 years, a close resection margin, and a high tumor grade were significantly associated with a high LRR (p=0.009, p \< 0.001, and p=0.005, respectively). T2 stage was marginally significant with a high LRR (p=0.073). In multivariate analyses of LRR, a close resection margin was the only independent risk factor (hazard ratio \[HR\], 1.504; p=0.001), and age (HR, 1.721; p=0.076), high tumor grade (HR, 1.500; p=0.068), and TN biological subtype (HR, 1.596; p=0.095) were marginally significant factors for LRR.

Univariate analyses of AFR revealed that age ≤ 35 years, T2 stage, a close resection margin, two or three positive LNs, positive HR, and high tumor grade were independent risk factors for AFRs (p=0.001, p \< 0.001, p=0.023, p=0.010, p=0.483, and p \< 0.001, respectively). In multivariate analyses of AFRs, age ≤ 35 years (HR, 1.671; p=0.025), T2 stage (HR, 1.183; p=0.004), a close resection margin (HR, 1.228; p=0.035), a high tumor grade (HR, 1.409; p=0.032), and the TN biological subtype (HR, 1.550; p=0.031) were independent risk factors. Two or three positive LNs (HR, 1.312; p=0.078) were a marginally significant factor for AFR.

5. Risk stratification to identify PMRT indication
--------------------------------------------------

Because the purpose of our study was to identify patients who may benefit from PMRT mainly based on overall recurrence, we utilized risk factors proven to be independent in multivariate analyses for AFRs to define risk groups. The six risk factors were patients' age (≤ 35 years vs. \> 35 years), tumor size (T1 vs. T2), the resection margin status (negative vs. close), the number of metastatic LNs (1 vs. 2-3), tumor grade (low-intermediate vs. high), and biological subtype (TN vs. others). Two patients had no risk factors, and 411, 414, 241, 76, and 17 patents had one, two, three, four, and five risk factors, respectively. No patients had all six risk factors.

The risk of both LRR and AFR increased with increasing number of risk factors. The results stratified by risk group are illustrated in [Fig. 2](#f2-crt-2016-405){ref-type="fig"}. The 5-year cumulative LRR rates were 3.6% with 0-1 risk factor (n=606), 7.5% with 2-3 risk factors (n=655), and 12.7% with 4-6 risk factors (n=93). The 10-year cumulative LRR rates were 9.1% with 0-1 risk factor, 11.6% with 2-3 risk factors, and 17.5% with 4-6 risk factors ([Fig. 2A](#f2-crt-2016-405){ref-type="fig"}). The 5-year cumulative AFR rates were 7.1% with 0-1 risk factor, 15.0% with 2-3 risk factors, and 24.5% with 4-6 risk factors. The 10-year cumulative AFR rates were 12.8% with 0-1 risk factor, 22.3% with 2-3 risk factors, and 30.5% with 4-6 risk factors ([Fig. 2B](#f2-crt-2016-405){ref-type="fig"}).

Discussion
==========

PMRT following mastectomy in pT1-2N1 breast cancer patients has not been generally recommended because of the low risk of recurrence. Although the updated EBCTCG meta-analysis proved the benefit of PMRT in N1 and N2 patients who had axillary dissection and systemic therapy \[[@b5-crt-2016-405]\], the recent consensus from the St. Gallen breast cancer meeting in 2015 did not adopt the routine use of PMRT for all N1 patients, just those with adverse pathology \[[@b1-crt-2016-405]\]. The present study was designed to identify a subset of N1 patients who may benefit from PMRT.

The entire cohort did not receive PMRT after mastectomy. Our analysis showed that the 10-year AFR and LRR rates were 17.9% and 10.5%, respectively. These rates are comparable to those of the recent contemporary study by Lai et al. \[[@b12-crt-2016-405]\], which include almost the same study population with ours between 2004 and 2008 and utilized modern systemic treated for most of the patient. They reported the 10-year progression-free survival and LRR rates were 75.1% (24.9%, free from recurrence) and 10%, respectively. However, these results are far superior to the outcomes of the no-RT subset in the EBCTCG meta-analysis (the 10-year AFR and LRR rates were 45.7% and 20.3%, respectively). One possible explanation may be the difference in the number of positive LNs. The rates of only one positive LN were 58.8% in our cohort and 31.4% in the EBCTCG no-RT subset (34.9% were unknown). Our analysis did show a statistically significant difference in AFR between one and two or three positive LNs (p=0.010) but not in LRR (p=0.320) ([Table 3](#t3-crt-2016-405){ref-type="table"}). Similarly, in the EBCTCG no-RT and systemic therapy subset, the 10-year AFR rate was lower in the one positive LN group than in the two or three positive LN group (36.3% vs. 47.8%). The LRR rate was similar (20.2% vs. 19.3%). Another explanation could be the difference in the systemic treatment used in the two studies. In our study, 99.4% (1,374 of 1,382 patients) were treated with any type of systemic treatment (24% chemotherapy alone, 3% endocrine therapy alone, 73% both, and 0.6% none) ([Table 1](#t1-crt-2016-405){ref-type="table"}). On the other hand, 86% were treated with systemic treatment in the EBCTCG N1 subset (62% chemotherapy alone, 21% endocrine therapy alone, 3% both, and 14% none), and 87% were treated with systemic treatment in the EBCTCG N1 and no-RT subset (detailed information not shown). Importantly, the most common chemotherapy was cyclophosphamide, methotrexate, and fluorouracil, and the most common endocrine therapy was tamoxifen in the EBCTCG meta-analysis. On the other hand, 80% (1,104 of 1,382 patients) received a taxane-containing chemotherapy, and one-third of the patients received an aromatase inhibitor as endocrine therapy; more than half of the HER2-positive patients received trastuzumab in our cohort. Therefore, it is reasonable that these superior results of our analysis are attributable to modern systemic treatment \[[@b13-crt-2016-405],[@b14-crt-2016-405]\]; however, further discussion is beyond the scope of this study. The final possible explanation is that our data were immature to exhibit entire recurrence considering the long natural history of breast cancer. The studies included in the EBCTCG meta-analysis were carried out between 1964 and 1986, and the patients were followed up for more than 10 years (median follow-up period, 9.4 years). The patients in our study were treated between 2005 and 2010, and the median follow-up period was 5.9 years.

Although the difference in the LRR and AFR rates between our study and the EBCTCG meta-analysis seems large, the relationship between them is similar. The closest subset to our cohort in the EBCTCG meta-analysis was the N1 patients treated with systemic treatment and without PMRT. In this subset, the 5-year LRR rate was 17.4% and the 10-year AFR rate was 45.5%, which was 2.6 times higher. In our study, the 5-year LRR rate was 6.1% and the 10-year AFR rate was 17.9%, which was 2.9 times higher. Considering that PMRT reduced any recurrence by one-third in the EBCTCG meta-analysis, if PMRT were administered, the 10-year overall recurrence would be decreased to 12%. The EBCTCG data also showed that the 10-year AFR rate and 20-year breast cancer mortality rate were similar, and PMRT reduced the 20-year breast cancer mortality by more than one-fifth. We predict that the 20-year breast cancer mortality would be 18%; if PMRT were administered, this rate would decrease to 14% in our cohort.

Classification of breast cancer according to biological subtype has proven to be a strong predictor of LRR, DM, and survival \[[@b9-crt-2016-405],[@b15-crt-2016-405]-[@b19-crt-2016-405]\]. As mentioned above, the patients in the EBCTCG meta-analysis were diagnosed and treated more than 30 years ago. Thus, it did not address the effects of biological subtypes on the risk of recurrence, which is being utilized for treatment decision making and predicting the prognosis. This is one reason why PMRT could not be recommended for all N1 patients, despite evidence that PMRT does reduce LRR and increase survival. Our study's finding that patients with the luminal A subtype had lower rates of LRR and those with the TN subtype had higher rates of LRR relative to other subtypes is similar to other studies in the setting of mastectomy \[[@b12-crt-2016-405],[@b16-crt-2016-405],[@b18-crt-2016-405],[@b20-crt-2016-405]\]. In the systemic review by Lowery et al. \[[@b16-crt-2016-405]\], the luminal, HER2-overexpressing, and TN tumor subtypes were defined according to the expression of ER, PR, and HER receptor as determined by immunohistochemical staining. Luminal tumors were less likely to develop LRR than HER2-overexpressing or TN tumors, but there were no differences in LRR between HER2-overexpressing and TN tumors following mastectomy. Tseng et al. \[[@b18-crt-2016-405]\] defined five biological subtypes, which were the same as ours, and evaluated LRR after mastectomy and the impact of PMRT by breast cancer subtype. Compared to luminal A patients, TN patients had the highest risk of LRR and the least benefit from PMRT. Patients with HER2 tumors treated with trastuzumab had a low risk of LRR. However, in our study, the use of trastuzumab in HER2 tumors did not affect LRR or AFR.

We defined AFR as the primary endpoint, similar to the EBCTCG meta-analysis. Therefore, to suggest a PMRT indication in N1, we utilized the risk factors by multivariate analyses of AFR to identify a high-risk subgroup. The 10-year AFR rates were as follows: 30.5% with four or more risk factors present simultaneously (young age, T2 tumors, a close resection margin, high-grade tumors, and the TN subtype); 22.3% with 2-3 risk factors, and 12.8% with 0-1 risk factor. If the proportional risk reductions were applied to each risk group after adding PMRT, the 10-year AFR rates would decline to the following: 22.8% with 4 or more risk factors, 16.7% with 2-3 risk factors, and 9.6% with 0-1 risk factor, respectively. However, in the latter group, the absolute gain of the overall recurrence would be only 3.2%.

This retrospective study had several limitations. First, pathologic findings such as HR/HER2 positivity or tumor grade were not centrally reviewed or reassessed according to common criteria. Criteria discrepancies among participating institutions might hamper an accurate analysis. Second, the follow-up period was relatively short, and our data on patient deaths were all-cause mortality. Therefore, our study could not address survival benefits related to overall recurrence reduction obtained by PMRT in T1-2N1 patients. Despite these limitations, our study had important strengths. This was a large cohort study in which 1,382 T1-2N1 breast cancer patients treated with mastectomy without PMRT were included. About half (n=682) patients were included in N1 and no-RT subset of EBCTCG meta-analysis compared to our study cohort. More importantly, because our study adopted current diagnostic and therapeutic strategies, the conclusions drawn by our analyses are more relevant to real practice than those of the EBCTCG meta-analysis.

The United Kingdom Medical Research Council SUPREMO (Selective Use of Postoperative Radiotherapy After Mastectomy) trial, which randomly allocated approximately 1,600 patients with high-risk N0 as well as N1, completed patients accrual \[[@b21-crt-2016-405]\]. We expect that the result of this trial help clarify the indication of PMRT.

Conclusion
==========

In summary, patients with pT1-2N1 breast cancer who underwent mastectomy and optimal systemic therapy showed favorable LRR and overall recurrence without PMRT. However, the concomitant presence of multiple risk factors contributes to higher tumor recurrence. The patients with four or more risk factors may benefit from PMRT, and those with two or three risk factors merit consideration of PMRT. In addition, PMRT may be omitted for patients without risk factors and with only one risk factor because the absolute benefits are small.
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###### S1 Fig.

Loco-regional recurrence (A) and any first recurrence (B) according to biological subtype

![Cumulative incidence of loco-regional recurrence, any first recurrence, and overall mortality.](crt-2016-405f1){#f1-crt-2016-405}

![Increased risk of loco-regional recurrence (A) and any first recurrence (B) with increasing number of risk factors.](crt-2016-405f2){#f2-crt-2016-405}

###### 

Patient, tumor, and treatment characteristics

  Variable                      No. (%) (n=1,382)
  ----------------------------- -------------------
  **Age, median (range, yr)**   48 (24-85)
  **Menopausal status**         
   Premenopausal                841 (60.9)
   Postmenopausal               530 (38.4)
   Unknown                      11 (0.8)
  **T stage**                   
   T1                           562 (40.7)
   T2                           820 (59.3)
  **Tumor histologic grade**    
   Low-intermediate             807 (58.4)
   High                         547 (39.6)
   Unknown                      28 (2.0)
  **Resection margin**          
   Negative (≥ 2 mm)            1,193 (86.3)
   Close (\< 2 mm)              189 (13.7)
  **No. of nodes examined**     
   Median                       15 (1-64)
   \< 10                        275 (19.9)
   ≥ 10                         1,107 (80.1)
  **No. of positive nodes**     
   1                            813 (58.8)
   2                            371 (26.8)
   3                            198 (14.3)
  **Hormonal receptor**         
   Positive                     1,022 (74.0)
   Negative                     360 (26.0)
  ***HER2* amplification**      
   Positive                     407 (29.5)
   Negative                     917 (66.4)
   Unknown                      58 (4.2)
  **Systemic treatment**        
   Endocrine therapy alone      41 (3.0)
   Chemotherapy alone           328 (23.7)
   Both                         1,005 (72.7)
   Neither                      8 (0.6)
  **Chemotherapy**              
   Taxane-containing            1,104 (79.9)
   Non-taxane containing        229 (16.6)
   Not done                     49 (3.5)
  **Trastuzumab**               
   HER2+ and trastuzumab--      154 (11.1)
   HER2+ and trastuzumab+       253 (18.3)
  **Biological subtype**        
   Luminal A                    554 (40.1)
   Luminal B                    187 (13.5)
   Luminal HER2                 209 (15.1)
   HER2+                        198 (14.3)
   Triple negative              157 (11.4)
   Unknown                      77 (5.6)

HER2, human epidermal growth factor receptor 2.

###### 

Patterns of failure

  Site of recurrence   No. (%)
  -------------------- ------------
  **Local**            39 (2.8)
  **Regional**         70 (5.1)
   Axilla              54 (3.9)
   Internal mammary    36 (2.6)
   Supraclavicular     47 (3.4)
  **Loco-regional**    91 (6.6)
  **Distant**          138 (10.0)

###### 

Univariate and multivariate analysis for loco-regional recurrence and any first recurrence

  Variable                                                  Total (n=1,382)   Loco-regional recurrence   Any first recurrence                                                          
  --------------------------------------------------------- ----------------- -------------------------- ---------------------- ------- --------------------- ----- ---------- ------- ---------------------
  **Age (yr)**                                                                                                                                                                         
   ≤ 35                                                     101               13                         0.009                  0.076   1.721 (0.945-3.136)   23    0.001      0.025   1.671 (0.068-2.615)
   \> 35                                                    1,281             78                                                                              150                      
  **T stage**                                                                                                                                                                          
   T1                                                       562               29                         0.073                  0.298   1.084 (0.932-1.260)   47    \< 0.001   0.004   1.183 (1.056-1.326)
   T2                                                       820               62                                                                              126                      
  **Resection margin**                                                                                                                                                                 
   Negative                                                 1,193             68                         \< 0.001               0.001   1.504 (1.184-1.910)   140   0.023      0.035   1.228 (1.014-1.488)
   Close                                                    189               23                                                                              33                       
  **No. of positive nodes**                                                                                                                                                            
   1                                                        813               49                         0.320                  0.683   1.091 (0.717-1.662)   86    0.010      0.078   1.312 (0.970-1.774)
   2-3                                                      569               42                                                                              87                       
  **Tumor histologic grade**                                                                                                                                                           
   Low-intermediate                                         807               42                         0.005                  0.068   1.500 (0.971-2.318)   83    \< 0.001   0.032   1.409 (1.030-1.928)
   High                                                     547               48                                                                              89                       
   Unknown^[a)](#tfn1-crt-2016-405){ref-type="table-fn"}^   28                1                                                                               1                        
  **HER2 status**                                                                                                                                                                      
   Negative                                                 917               63                         0.714                  \-      \-                    122   0.483      \-      \-
   Positive and trastuzumab--                               154               12                                                                              21                       
   Positive and trastuzumab+                                253               13                                                                              25                       
   Unknown^[a)](#tfn1-crt-2016-405){ref-type="table-fn"}^   58                3                                                                               5                        
  **Biological subtype**                                                                                                                                                               
   Luminal A                                                554               26                         0.016                  \-      \-                    49    \< 0.001   \-      \-
   Luminal B                                                187               19                                                                              40                       
   Luminal HER2                                             209               12                                                                              24                       
   HER2+                                                    198               13                                                                              22                       
   Triple negative                                          157               17                                                                              32                       
   Unknown^[a)](#tfn1-crt-2016-405){ref-type="table-fn"}^   77                4                                                                               6                        
  **Biological subtype**                                                                                                                                                               
   Triple negative                                          157               17                         0.026                  0.095   1.596 (0.923-2.761)   32    0.001      0.031   1.550 (1.041-2.039)
   Others                                                   1,225             74                                                                              141                      

HER2, human epidermal growth factor receptor 2.

Patients with unknown tumor grade, HER2 status, or biological subtype were not included in the statistical analysis.
